Cryopreserved hematopoietic stem/progenitor cells stability program‐development, current status and recommendations: A brief report from the AABB‐ISCT joint working group cellular therapy product stability project team. Issue 3 (20th March 2022)

• Record Type: Journal Article
• Authors: Reich‐Slotky, Ronit; Vasovic, Ljiljana V.; Land, Kevin J.; Halpenny, Mike; Woeltz, Joan; Mathew, Aby J.; Fournier, Diane; Alder, Brenda; Stasko, Karl; Mahmud, Nadim
• Is Part Of: Transfusion. Volume 62:Issue 3(2022)
• Page Start: 651
• Page End: 662
• Publication Date: 2022-03-20
• Subjects: CD34+ cell -- cryopreservation -- functional assay -- hematopoietic stem/progenitor cells -- potency -- recovery -- stability; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16820
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: The AABB‐ISCT Joint Working Group Stability Project Team (SPT) was assigned to roadmap a path toward standardization of cryopreserved hematopoietic stem/progenitor cell (HSPC) stability programs. HSPC stability encompasses a broad scope of conditions including non‐frozen ("fresh") and cryopreserved cell products, and varying methods for storage, thaw, and administration. This report assessed current practices and focused solely on cryopreserved HSPC cell therapy products to establish preliminary recommendations for a stability program roadmap. Methods: A survey was prepared by the SPT and distributed to ISCT and AABB members. Survey results were summarized and recommendations were outlined based on the responses from the survey. This report highlights current practices for cryopreserved HSPC stability programs, including additional considerations and recommendations. Results and Discussion: Eighty‐two (82) centers worldwide participated in the survey. Survey results indicate variability across programs. HSPC stability depends on multiple factors within the processing facility (e.g., cryopreservation techniques, reagents used, and storage temperature) and independent variables (e.g., donor‐related factors and starting material variability). While retention of hematopoietic engraftment potential is the primary goal for cryopreserved HSPC stability, engraftment results should not be used as the sole metric for stability programs. Based on the survey results, the SPT provides recommendations for consideration. Conclusions: The SPT recommendations for best practices are not intended to replace existing standards. The survey results emphasize the need for the community to optimize best practices and consider initiating collaborative projects to improve the standardization of cryopreserved HSPC stability programs for cell therapy products.